In conclusion, on the basis of proteomics, metabolomics, and animal experiments, this study demonstrated that QRHXD could reduce disease activity and the inflammatory response in RA patients while delaying bone destruction in CIA mice, by inhibiting FBP1 and activating the AMPK signalling pathway. This evidence concerns the gene FBP1 and rheumatoid arthritis.